Exosomes derived from human adipose tissue-derived mesenchymal stem cells for the treatment of dupilumab-related facial redness in patients with atopic dermatitis: A report of two cases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Kui Young | - |
dc.contributor.author | Han, Hye Sung | - |
dc.contributor.author | Park, Jae Wan | - |
dc.contributor.author | Kwon, Hyuck Hoon | - |
dc.contributor.author | Park, Gyeong-Hun | - |
dc.contributor.author | Seo, Seong Jun | - |
dc.date.accessioned | 2021-11-15T08:40:13Z | - |
dc.date.available | 2021-11-15T08:40:13Z | - |
dc.date.issued | 2022-02 | - |
dc.identifier.issn | 1473-2130 | - |
dc.identifier.issn | 1473-2165 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/51420 | - |
dc.description.abstract | Background Atopic dermatitis is a chronic, pruritic, and inflammatory dermatosis that affects approximately 20% of children and 10% of adults worldwide. Dupilumab facial redness is gaining attention as additional cases are coming to light in the medical literature. Objectives and methods Exosomes are nano-sized vesicles that are constantly released by almost all cells. They can travel between cells and transport their cargo (lipids, proteins, and nucleic acids), making them a possible cell-free therapeutic option for various diseases. Herein, we investigated whether topical application of human adipose tissue-derived mesenchymal stem cell-derived exosomes could reduce dupilumab facial redness in patients with severe atopic dermatitis. Results Two patients with atopic dermatitis and refractory dupilumab facial redness were successfully treated with electroporation-assisted topical application of human adipose tissue-derived mesenchymal stem cell-derived exosomes. Six repeated sessions of treatment, with an interval of 1 week between each session, led to marked improvement in erythematous facial lesions. Conclusions We suggest that human adipose tissue-derived mesenchymal stem cell-derived exosomes may serve as an effective agent in the management of dupilumab facial redness. However, further controlled studies with a larger number of patients are necessary to confirm the efficacy and safety of this agent, as well as the optimal treatment protocol. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Exosomes derived from human adipose tissue-derived mesenchymal stem cells for the treatment of dupilumab-related facial redness in patients with atopic dermatitis: A report of two cases | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/jocd.14153 | - |
dc.identifier.bibliographicCitation | JOURNAL OF COSMETIC DERMATOLOGY, v.21, no.2, pp 844 - 849 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000645463200001 | - |
dc.identifier.scopusid | 2-s2.0-85105122421 | - |
dc.citation.endPage | 849 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 844 | - |
dc.citation.title | JOURNAL OF COSMETIC DERMATOLOGY | - |
dc.citation.volume | 21 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | atopic dermatitis | - |
dc.subject.keywordAuthor | dupilumab facial redness | - |
dc.subject.keywordAuthor | exosome | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.